1. Home
  2. FLNG vs NTLA Comparison

FLNG vs NTLA Comparison

Compare FLNG & NTLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FLEX LNG Ltd.

FLNG

FLEX LNG Ltd.

HOLD

Current Price

$31.00

Market Cap

1.7B

ML Signal

HOLD

Logo Intellia Therapeutics Inc.

NTLA

Intellia Therapeutics Inc.

HOLD

Current Price

$10.89

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FLNG
NTLA
Founded
2006
2014
Country
Bermuda
United States
Employees
N/A
N/A
Industry
Marine Transportation
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
1.7B
IPO Year
2019
2016

Fundamental Metrics

Financial Performance
Metric
FLNG
NTLA
Price
$31.00
$10.89
Analyst Decision
Hold
Buy
Analyst Count
1
23
Target Price
$23.00
$20.02
AVG Volume (30 Days)
347.0K
4.3M
Earning Date
05-13-2026
05-07-2026
Dividend Yield
9.40%
N/A
EPS Growth
N/A
27.43
EPS
N/A
N/A
Revenue
N/A
$67,671,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$2.14
$62.75
P/E Ratio
$19.72
N/A
Revenue Growth
N/A
16.92
52 Week Low
$24.00
$7.95
52 Week High
$33.40
$28.24

Technical Indicators

Market Signals
Indicator
FLNG
NTLA
Relative Strength Index (RSI) 53.78 32.00
Support Level $28.71 $8.59
Resistance Level $31.31 $15.52
Average True Range (ATR) 0.83 0.80
MACD 0.06 -0.35
Stochastic Oscillator 74.73 10.20

Price Performance

Historical Comparison
FLNG
NTLA

About FLNG FLEX LNG Ltd.

Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The company's fleet consists of several LNG carriers on the water, and all of its vessels are of the latest generation equipped with two-stroke propulsion. Its fleet consists of M-type, Electronically Controlled, Gas Injection (MEGI) LNG carriers and Generation X Dual Fuel (X-DF) LNG carriers, offering improvements in fuel efficiency and thus also carbon footprint compared to the older steam and four-stroke propelled ships. The company has one reportable segment: vessel operations, which generates revenue from the chartering of vessels to customers.

About NTLA Intellia Therapeutics Inc.

Intellia Therapeutics is a gene-editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. Intellia is focused on using this technology to treat genetically defined diseases. It's evaluating multiple gene editing approaches using in vivo and ex vivo therapies to address diseases with high unmet medical needs, including ATTR amyloidosis, hereditary angioedema, sickle cell disease, and immuno-oncology. Intellia has formed collaborations with several companies to advance its pipeline, including narrow-moat Regeneron and wide-moat Novartis.

Share on Social Networks: